Literature DB >> 12612993

Incidence and prediction of nonmelanoma skin cancer post-renal transplantation: a prospective study in Queensland, Australia.

Robert P Carroll1, Helen M Ramsay, Anthony A Fryer, Carmel M Hawley, David L Nicol, Paul N Harden.   

Abstract

BACKGROUND: Nonmelanoma skin cancer (NMSC) is a significant clinical problem after renal transplantation, particularly in areas of high UV light exposure. A single-center prospective study of a population of Queensland renal transplant recipients was performed with the aims of: (1) establishing NMSC incidence and tumor accrual post-renal transplantation, and (2) developing a clinically derived predictive index to identify transplant recipients at greatest risk.
METHODS: Three hundred ten of 398 transplant recipients (78%) who underwent baseline assessment between July 1999 and April 2000 were reassessed a mean of 18 +/- 3.5 (SD) months later. A structured interview, full skin examination, biopsy of suspicious lesions, and review of medical and pathological records were used to determine the number and types of NMSC arising between the two assessments. Incidence (percentage of the population developing NMSC per year) and tumor accrual (number of tumors per person per year) were calculated. A clinically derived predictive index was generated using stepwise logistic regression models.
RESULTS: Overall NMSC incidence was 28.1% and increased with duration of immunosuppression therapy: 18.8%, 24.8%, 33.3%, and 47.1% at less than 5, 5 to 10, 10 to 20, and greater than 20 years of immunosuppression therapy, respectively. Mean NMSC accrual was 1.85 +/- 3.84 tumors/person/y, increasing to 3.35 +/- 4.29 tumors/person/y after 20 years of immunosuppression therapy. Renal transplant recipients were stratified into categories of high and low NMSC risk by using predictive indices.
CONCLUSION: Clinically derived predictive indices can allow NMSC risk stratification of an Australian transplant population and may provide an evidence-based and cost-effective approach to developing a targeted clinical NMSC surveillance program. Copyright 2003 by the National Kidney Foundation, Inc.

Entities:  

Mesh:

Year:  2003        PMID: 12612993     DOI: 10.1053/ajkd.2003.50130

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  25 in total

1.  Squamous cell carcinoma with rhabdoid phenotype and osteoclast-like giant cells in a renal-pancreas transplant recipient.

Authors:  K Aljerian; K O Alsaad; R Chetty; D Ghazarian
Journal:  J Clin Pathol       Date:  2006-12       Impact factor: 3.411

Review 2.  Immune profiling and cancer post transplantation.

Authors:  Christopher Martin Hope; Patrick Toby H Coates; Robert Peter Carroll
Journal:  World J Nephrol       Date:  2015-02-06

3.  Vorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model.

Authors:  Deepali Kurundkar; Ritesh K Srivastava; Sandeep C Chaudhary; Mary E Ballestas; Levy Kopelovich; Craig A Elmets; Mohammad Athar
Journal:  Toxicol Appl Pharmacol       Date:  2012-11-09       Impact factor: 4.219

4.  Yearly Burden of Skin Cancer in Non-Caucasian and Caucasian Solid-organ Transplant Recipients.

Authors:  Arlene M Ruiz DE Luzuriaga; Clifford Hsieh
Journal:  J Clin Aesthet Dermatol       Date:  2015-03

5.  Immune phenotype predicts risk for posttransplantation squamous cell carcinoma.

Authors:  Robert P Carroll; David San Segundo; Kevin Hollowood; Teresa Marafioti; Taane G Clark; Paul N Harden; Kathryn J Wood
Journal:  J Am Soc Nephrol       Date:  2010-01-28       Impact factor: 10.121

6.  A preliminary study of a video intervention to inform solid organ transplant recipients about skin cancer.

Authors:  L J Loescher; C Hansen; J T Hepworth; L Quale; J Sligh
Journal:  Transplant Proc       Date:  2013-06-06       Impact factor: 1.066

Review 7.  Keratinocyte Carcinomas: Current Concepts and Future Research Priorities.

Authors:  Priyadharsini Nagarajan; Maryam M Asgari; Adele C Green; Samantha M Guhan; Sarah T Arron; Charlotte M Proby; Dana E Rollison; Catherine A Harwood; Amanda Ewart Toland
Journal:  Clin Cancer Res       Date:  2018-12-06       Impact factor: 12.531

8.  Cyclosporine A immunosuppression drives catastrophic squamous cell carcinoma through IL-22.

Authors:  Melody Abikhair; Hiroshi Mitsui; Valerie Yanofsky; Nazanin Roudiani; Channa Ovits; Teddy Bryan; Tatiana M Oberyszyn; Kathleen L Tober; Juana Gonzalez; James G Krueger; Diane Felsen; John A Carucci
Journal:  JCI Insight       Date:  2016-06-02

9.  UVB radiation-mediated inhibition of contact hypersensitivity reactions is dependent on the platelet-activating factor system.

Authors:  Qiwei Zhang; Yongxue Yao; Raymond L Konger; Anthony L Sinn; Shanbao Cai; Karen E Pollok; Jeffrey B Travers
Journal:  J Invest Dermatol       Date:  2008-01-17       Impact factor: 8.551

Review 10.  Current concepts and perspectives of immunosuppression in organ transplantation.

Authors:  Marcus N Scherer; Bernhard Banas; Kiriaki Mantouvalou; Andreas Schnitzbauer; Aiman Obed; Bernhard K Krämer; Hans J Schlitt
Journal:  Langenbecks Arch Surg       Date:  2007-04-21       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.